RBC Capital Reiterates Outperform on HOOKIPA Pharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on HOOKIPA Pharma (NASDAQ:HOOK) and maintained a price target of $7.
September 27, 2023 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating on HOOKIPA Pharma and maintained a price target of $7.
The reiteration of the 'Outperform' rating and maintenance of the $7 price target by RBC Capital indicates a positive outlook for HOOKIPA Pharma. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100